This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jens D. Lundgren, MD, DMSc; Court Pedersen, MD, DMSc; Jens Ole Nielsen, MD, DMSc
University of Copenhagen Copenhagen, Denmark

Andrew N. Phillips, PhD
Royal Free Hospital London, England

JAMA. 1994;272(13):1001-1002.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We appreciate the interest in the results presented in our recent publication. Drs Berman and Wenglin are correct in their interpretation of our results insofar as zidovudine seems to have a beneficial influence on survival when it is initiated in patients with advanced human immunodeficiency virus (HIV) infection. As also pointed out in the "Comment" section of our article, the results agree with the only placebo-controlled study¹ and several observational studies² in patient groups with similar advanced HIV infection as in our population (ie, a survival benefit within the first months after starting zidovudine). However, because of the large number of patients studied, we were also able to suggest whether the effect persisted for extended periods of time; we found this not to be true. Whether optimal dosage and combination antiretroviral therapy will eventually affect survival of AIDS patients, as suggested by Berman and Wenglin, awaits . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?